Carbapenem resistance is a major and an on-going public health problem globally. It occurs
mainly among Gram-negative pathogens such as Klebsiella pneumoniae, Pseudomonas …

The carbapenems are β-lactam antimicrobial agents with an exceptionally broad spectrum
of activity. Older carbapenems, such as imipenem, were often susceptible to degradation by …

The prescription of pharmaceuticals in the critically ill is complicated by a paucity of
knowledge concerning the pharmacokinetic implications of the underlying disease state …

Augmented renal clearance (ARC) is a manifestation of enhanced renal function seen in
critically ill patients. The use of regular unadjusted doses of renally eliminated drugs in …

Abstract Treatment of sepsis remains a significant challenge with persisting high mortality
and morbidity. Early and appropriate antibacterial therapy remains an important intervention …

Summary Abstract Meropenem (Merrem®, Meronem®) is a broad-spectrum antibacterial
agent of the carbapenem family, indicated as empirical therapy prior to the identification of …

Objective: Doripenem is an investigational carbapenem with broad-spectrum activity against
Gram-negative and Gram-positive pathogens, including multidrug-resistant strains …

Continuous renal replacement therapy (CRRT), particularly continuous venovenous
haemofiltration (CVVH) and continuous venovenous haemodiafiltration (CVVHDF), are …

Imipenem, the first carbapenem discovered, was developed more than two decades ago in
response to an unmet need for a highly potent, broad-spectrum antimicrobial agent with a …

Imipenem‐cilastatin‐relebactam (IMI‐REL) is a novel β‐lactam–β‐lactamase inhibitor
combination recently approved for the treatment of complicated urinary tract infections …